<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762915</url>
  </required_header>
  <id_info>
    <org_study_id>DENT-2018-27312</org_study_id>
    <nct_id>NCT03762915</nct_id>
  </id_info>
  <brief_title>Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg</brief_title>
  <official_title>Effect of Non-Surgical Periodontal Therapy With and Without Minocycline HCl Microspheres, 1 mg on Bacterial Load and Systemic Markers of Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch Health Companies, INC.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to investigate the qualitative and quantitative effects of&#xD;
      scaling and root planing (SRP) with and without minocycline HCL microspheres, 1 mg on&#xD;
      periodontal pathogens and overall bacterial load.&#xD;
&#xD;
      A randomized controlled clinical trial of a control (SRP) group and an experimental (SRP with&#xD;
      minocycline HCl microspheres, 1 mg) group is planned.&#xD;
&#xD;
      Specific Aim 1: Evaluate the cumulative oral periodontal bacterial burden in both control and&#xD;
      test groups over a six month period.&#xD;
&#xD;
      Specific Aim 2: Assess gingival crevicular fluid (GCF) and serum biomarkers of inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized controlled clinical trial of a control (SRP) group and an experimental (SRP with&#xD;
      minocycline HCl microspheres, 1 mg) group is planned.&#xD;
&#xD;
      The intervention of minocycline HCl microspheres, 1 mg will be administered in the&#xD;
      experimental group at baseline and the three month periodontal maintenance visit. Saliva&#xD;
      samples, GCF, and blood serum will be collected at four time points (baseline, 1, 3, and 6&#xD;
      month follow up). Saliva will be analyzed for overall pathogen burden. GCF will be analyzed&#xD;
      for Interleukin (IL)-1, IL-6, and tumor necrosis factor alpha (TNF-α). Serum will be analyzed&#xD;
      for C-reactive protein (hsCRP), haptoglobin (Hp), hemoglobin A1c (Hgb A1c), IL-1, IL-6, and&#xD;
      TNF-α.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Pathogenic Burden</measure>
    <time_frame>baseline, 1, 3, and 6 months</time_frame>
    <description>Scale 0-100</description>
  </primary_outcome>
  <other_outcome>
    <measure>GCF markers</measure>
    <time_frame>baseline, 1, 3, and 6 months</time_frame>
    <description>Change in picograms per mililitre (pg/ML)</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Markers</measure>
    <time_frame>baseline, 1, 3, and 6 months</time_frame>
    <description>Change in picograms per mililitre (pg/ML) to known reference range</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>SRP</condition>
  <condition>Minocycline HCl Microspheres</condition>
  <condition>Biomarkers</condition>
  <arm_group>
    <arm_group_label>SRP with minocycline HCl microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP without minocycline HCl microspheres</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will not have minocycline HCl microspheres, 1 mg administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>minocycline HCl microspheres</intervention_name>
    <description>Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.</description>
    <arm_group_label>SRP with minocycline HCl microspheres</arm_group_label>
    <other_name>Arestin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and Female&#xD;
&#xD;
          -  At least 21 years of age&#xD;
&#xD;
          -  ADA Class III-IV Chronic Periodontitis&#xD;
&#xD;
          -  Scaling and Root Planing (SRP) or localized SRP&#xD;
&#xD;
          -  A minimum of eight sites with pockets ≥5mm with bleeding on probing (any quadrant)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with study protocol&#xD;
&#xD;
          -  Completed treatment of Scaling and Root Planing (SRP) and/or localized SRP within the&#xD;
             last 6 months&#xD;
&#xD;
          -  Cigarette use within the last year&#xD;
&#xD;
          -  ≥2 weeks of antibiotic use in the past three months. Or antibiotic use in the last six&#xD;
             weeks.&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or unsure of pregnancy status (self- reported)&#xD;
&#xD;
          -  Diagnosed cardiac conditions (cardiovascular disease (CVD) or atherosclerotic vascular&#xD;
             disease (ASVD) including coronary heart disease, cerebrovascular disease, and&#xD;
             peripheral artery disease, myocardial infarction, stroke, stable or unstable angina,&#xD;
             transient ischemic attack, or coronary or other arterial revascularization&#xD;
&#xD;
          -  Have any uncontrolled medical condition or immunocompromised that may impact the study&#xD;
             (uncontrolled diabetes HbA1c &gt; 7, HIV, etc.)&#xD;
&#xD;
          -  Tetracycline allergy&#xD;
&#xD;
          -  Any medication that may impact periodontal conditions (Phenytoin, calcium antagonists,&#xD;
             cyclosporin, warfarin, or NSAIDS)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Arnett</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 28, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2018</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

